IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment.

ABSTRACT:

Background

Glioblastoma multiforme (GBM) is an aggressive brain tumor with chemoresistant, immunosuppressive, and invasive properties. Despite standard therapies, including surgery, radiotherapy, and temozolomide (TMZ) chemotherapy, tumors inevitably recur in the peritumoral region. Targeting GBM-mediated immunosuppressive and invasive properties is a promising strategy to improve clinical outcomes.

Methods

We utilized clinical and genomic data from the Taiwan GBM cohort and The Cancer Genome Atlas (TCGA) to analyze RNA sequencing data from patient tumor samples, determining the association of interleukin-19 (Il-19) expression with survival and immunosuppressive activity. Gene set enrichment analysis (GSEA) was performed to assess the relationship between the enrichment leve

SUBMITTER: Lee GA 

PROVIDER: S-EPMC11889942 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature